Aclaris Therapeutics to Participate in Two February Healthcare Conferences

Stock Information for Aclaris Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aclaris Therapeutics Inc.

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4R? Antibody ATI-052
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4R? Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.